JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
115 hedge funds and large institutions have $271M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 25 closing their positions.
Holders
115
Holders Change
-15
Holders Change %
-11.54%
% of All Funds
2.02%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
11
Increased
44
Reduced
35
Closed
25
Calls
$570K
Puts
$180K
Net Calls
+$390K
Net Calls Change
+$1.78M
Top Buyers
| 1 |
LGM
1
Logos Global Management
San Francisco,
California
|
$14.9M |
| 2 |
RI
2
RTW Investments
New York
|
$10.4M |
| 3 |
PHS
3
PFM Health Sciences
San Francisco,
California
|
$28.6M |
| 4 |
4
Goldman Sachs
New York
|
$5.01M |
| 5 |
O
5
OrbiMed
New York
|
$19.7M |
